Show simple item record

dc.contributor.authorKanjanapan, Y
dc.contributor.authorDeb, S
dc.contributor.authorYoung, RJ
dc.contributor.authorBressel, M
dc.contributor.authorMileshkin, L
dc.contributor.authorRischin, D
dc.contributor.authorHofman, MS
dc.contributor.authorNarayan, K
dc.contributor.authorSiva, S
dc.date.accessioned2020-12-10T00:51:14Z
dc.date.available2020-12-10T00:51:14Z
dc.date.issued2017-02-01
dc.identifierpii: S2405-6308(16)30032-5
dc.identifier.citationKanjanapan, Y., Deb, S., Young, R. J., Bressel, M., Mileshkin, L., Rischin, D., Hofman, M. S., Narayan, K. & Siva, S. (2017). Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2, pp.53-58. https://doi.org/10.1016/j.ctro.2017.01.003.
dc.identifier.issn2405-6308
dc.identifier.urihttp://hdl.handle.net/11343/253591
dc.description.abstractBackground/purpose: Chemoradiation (CRT) is standard therapy for locally advanced cervical cancer (LACC). However, there is a lack of biomarkers to identify patients at high relapse-risk. We examine metabolic (glucose transporter-1 [Glut-1]), hypoxic (hypoxia inducible factor [HIF-1α]; carbonic anhydrase [CA-9]) and proliferative (Ki-67) markers for prognostic utility in LACC. Materials/methods: 60 LACC patients treated with CRT had pre-treatment biopsies. Immunohistochemistry was performed for Glut-1, HIF-1a and CA-9, to generate a histoscore from intensity and percentage staining; and Ki-67 scored by percentage of positive cells. For each biomarker, treatment response and survival was compared between low and high-staining groups by logrank testing and multivariate analyses. Results: High Glut-1 expression was associated with inferior progression-free survival (PFS), (hazard ratio [HR] 2.8, p = 0.049) and overall survival (OS), (HR 5.0, p = 0.011) on multifactor analysis adjusting for stage, node positivity, tumour volume and uterine corpus invasion. High Glut-1 correlated with increased risk of distant failure (HR 14.6, p = 0.001) but not local failure. Low Glut-1 was associated with higher complete metabolic response rate on post-therapy positron emission tomography scan (odds ratio 3.4, p = 0.048). Ki-67 was significantly associated with PFS only (HR 1.19 per 10 units increase, p = 0.033). Biomarkers for hypoxia were not associated with outcome. Conclusions: High Glut-1 in LACC is associated with poor outcome post CRT. If prospectively validated, Glut-1 may help select patients for more intensive treatment regimens.
dc.languageEnglish
dc.publisherELSEVIER IRELAND LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleGlut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation
dc.typeJournal Article
dc.identifier.doi10.1016/j.ctro.2017.01.003
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedical Education
melbourne.affiliation.departmentObstetrics and Gynaecology
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleClinical and Translational Radiation Oncology
melbourne.source.volume2
melbourne.source.pages53-58
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1323063
melbourne.contributor.authorHofman, Michael
melbourne.contributor.authorRischin, Danny
melbourne.contributor.authorSiva, Shankar
melbourne.contributor.authorMileshkin, Linda
melbourne.contributor.authorNarayan, Kailash
dc.identifier.eissn2405-6308
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record